Pharmaguy's Insights Into Drug Industry News
194.6K views | +7 today
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy!

PwC Predicts Patients Sharing Data Directly with #Pharma Will Be Valuable in 2017

PwC Predicts Patients Sharing Data Directly with #Pharma Will Be Valuable in 2017 | Pharmaguy's Insights Into Drug Industry News |

PwC's pharma and healthcare predictions for 2017 are out. And though, yes, next year may be "a year of uncertainty" with U.S. President-elect Donald Trump set to step in, it's also a year of "opportunity," the consultancy says.

One forecast pharma might want to heed? Patient connections, which aren’t necessarily anything new, will be increasingly valuable, PwC points out.

“Everybody wins when engagement takes place. Pharmaceutical companies would learn more about how patients manage their medications, and insurers could appreciate that patients are more likely to be adherent and meet their outcomes. There’s a domino effect," Fran Kochman, director of advocacy and alliance development at GlaxoSmithKline, said in the report.

And some patients have shown they're up for connecting directly with pharma. PwC’s Health Research Institute (HRI) found in 2016 that the majority of consumers with chronic conditions are willing to share their health data with pharma companies, including how well treatments are working and information about daily symptoms.

No comment yet.
Scooped by Pharma Guy!

Do Marketing Buzzwords Affect Pharma's Reputation Among Patients & Physicians?

Do Marketing Buzzwords Affect Pharma's Reputation Among Patients & Physicians? | Pharmaguy's Insights Into Drug Industry News |

These terms are part of the marketing lexicon, which is not shared with pharma marketers' "target" audiences. It's only in the closed, small world of industry conferences, ad agency press releases, and marketers' LinkedIn pages that these terms are seen and heard. Therefore, my guess is that marketing speak has little effect on pharma's reputation among ordinary, every day patients and physicians.

Nevertheless, when pharma marketers use these buzzwords, I take out my "gun" because I, like Spong, do not trust that they are "truly putting patients at the heart of [their] business approach," whatever that means within a capitalistic organization these days. I know what Mr. Merck said about profits follow when the company puts patients first, but these days Big Pharma puts Wall Street interests first.

Pharma Guy's insight:

The industry has "abstained" from using a couple of these buzzwords, at least within topics presented at industry conferences. "Multi-Channel Marketing" and "market access" are still frequently-used terms, but "sales force effectiveness" and "closed-loop marketing" are hardly to be heard nowadays at industry conferences.

No comment yet.
Scooped by Pharma Guy!

What’s You Company’s “Patient Engagement Maturity Level?”

What’s You Company’s “Patient Engagement Maturity Level?” | Pharmaguy's Insights Into Drug Industry News |

With regard to patient engagement, there is emerging support for moving away from a reactive approach, in which coordination between stakeholders, therapy, and care is limited or ad hoc, to a proactive model in which engagement tools and support bolster both patients and health care providers.


The five key needs that a comprehensive patient services suite should address are:


  1. Therapy: Connecting with patients to provide access to and support with their care. Specific therapy-related solutions include access to care, specialty pharmacy triage, distribution solutions, site of care/infusion site match, lab/test results coordination, and nurse visits.
  2. Financial: Helping patients obtain the resources they require to stay on therapy. Specific financial solutions include insurance verification, benefits investigation, claims appeals and re-coding, prior authorization, co-pay assistance, and bridge therapy programs.
  3. Clinical: Providing patients with a point of contact during trials and assisting with transitioning from clinical to commercial drugs, specifically clinical trial support and risk evaluation and mitigation strategies.
  4. Engagement: Granting patients access to programs via traditional and emerging channels that will help support their unique treatment journeys and enable better long-term treatment outcomes. Specific engagement-related solutions include enrollment and consent, case management, patient adherence programs, portals, assistance with appointments and scheduling, mobile health monitoring, telehealth, and advocacy.
  5. Education: Delivering educational insights to inform patient decision-making and behaviors. Solutions include medical information and pharmacovigilance, nursing educational support, and between-visit care.


Maturity levels across companies are highly variable; maturity in patient engagement has not been correlated to the overall maturity of the organization. In order to evaluate their current patient engagement maturity levels, pharma companies should examine their current patient engagement strategy, service offerings, and enabling technology on the following parameters: More here…

No comment yet.